Wednesday, 20 October 2021

AstraZeneca says US trial data shows vaccine 79% effective

Reuters

LONDON – AstraZeneca says advanced trial data from a U.S. study on its Covid vaccine shows it is 79 per cent effective.

Although AstraZeneca’s vaccine has been authorised in more than 50 countries, it has not yet been given the green light in the US. The US study comprised 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got dummy shots. The results were announced Monday.

In a statement, AstraZeneca said its Covid-19 vaccine had a 79 per cent efficacy rate at preventing symptomatic Covid and was 100 per cent effective in stopping severe disease and hospitalisation. Investigators said the vaccine was effective across all ages, including older people — which previous studies in other countries had failed to establish.

The early findings from the US study are just one set of information AstraZeneca must submit to the Food and Drug Administration. An FDA advisory committee will publicly debate the evidence behind the shots before the agency decides whether to allow emergency use of the vaccine.

Scientists have been awaiting results of the US study in hopes it will clear up some of the confusion about just how well the shots really work.

Check Also

EU antitrust regulators to investigate Google’s online ads business

Alphabet unit Google has found itself in the EU antitrust spotlight again as regulators opened ...

Leave a Reply